WallStreetZenWallStreetZen

NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

RARE past revenue growth

How has RARE's revenue growth performed historically?
Company
19.52%
Industry
144.63%
Market
17.55%
RARE's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
RARE's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
RARE's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

RARE earnings and revenue history

Current Revenue
$434.2M
Current Earnings
-$606.6M
Current Profit Margin
-139.7%

RARE Return on Equity

Current Company
-369.5%
Current Industry
-63.5%
Current Market
188%
RARE's Return on Equity (-369.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when RARE announces earnings.

RARE Return on Assets

Current Company
-44.7%
Current Industry
2.9%
RARE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

RARE Return on Capital Employed

Current Company
-50.26%
Current Industry
19.5%
RARE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RARE vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
RARE$434.25M-$582.46M-$606.64M+53.18%N/A
INSM$305.21M-$645.53M-$749.57M+98.78%N/A
MDGL$0.00-$360.39M-$373.63MN/AN/A
AXSM$270.60M-$223.54M-$239.24M+440.80%N/A
SWTX$5.45M-$321.78M-$325.10M-94.52%N/A
View Top Biotech Stocks

RARE earnings dates

Next earnings date
Jun 6, 2024

Ultragenyx Pharmaceutical Earnings & Revenue FAQ

What were RARE's earnings last quarter?

On Invalid Date, Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q4 2023 earnings per share (EPS) of -$1.44, up 33.33% year over year. Total Ultragenyx Pharmaceutical earnings for the quarter were -$123.19 million. In the same quarter last year, Ultragenyx Pharmaceutical's earnings per share (EPS) was -$2.16.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.

What was RARE's earnings growth in the past year?

As of Q2 2024, Ultragenyx Pharmaceutical's earnings has grown year over year. Ultragenyx Pharmaceutical's earnings in the past year totalled -$606.64 million.

What is RARE's earnings date?

Ultragenyx Pharmaceutical's earnings date is Invalid Date. Add RARE to your watchlist to be reminded of RARE's next earnings announcement.

What was RARE's revenue last quarter?

On Invalid Date, Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q4 2023 revenue of $127.39 million up 23.27% year over year. In the same quarter last year, Ultragenyx Pharmaceutical's revenue was $103.35 million.

What was RARE's revenue growth in the past year?

As of Q2 2024, Ultragenyx Pharmaceutical's revenue has grown 19.52% year over year. This is 125.11 percentage points lower than the US Biotechnology industry revenue growth rate of 144.63%. Ultragenyx Pharmaceutical's revenue in the past year totalled $434.25 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.